Rep. Lou Correa (D-CA) is leading a bipartisan effort to advance research into psychedelic drug therapies for U.S. veterans.
The initiative seeks to accelerate treatment options for veterans struggling with mental health conditions. By expanding the scope of allowable medical research, proponents aim to provide alternatives for those who have not responded to traditional therapies.
Correa said, "we owe it to our veterans" to pursue these medical advancements. The effort follows a previous administrative push to prioritize the study of these substances in clinical settings.
This legislative push aligns with an executive order signed in April 2024 [1]. That order was designed to speed up the research process and increase the funding available for psychedelic drug therapies [1].
The bipartisan nature of the effort suggests a growing consensus in Washington regarding the potential of psychedelics to treat complex trauma, and depression. By leveraging the framework established by the 2024 order, Correa and his colleagues intend to move these therapies from experimental phases toward broader clinical application.
Advocates for the research argue that the urgency of the veteran mental health crisis requires a departure from standard pharmacological approaches. The goal is to create a structured, safe environment where these therapies can be administered, and studied under federal oversight.
“"we owe it to our veterans"”
The push for psychedelic research represents a shift in federal mental health strategy, moving toward the integration of previously restricted substances into veteran care. By building on a 2024 executive order, lawmakers are attempting to institutionalize these therapies, potentially lowering the regulatory barriers for clinical trials and increasing federal funding for non-traditional psychiatric treatments.
